文献速递儿童感染儿童呼吸

大剂量静脉免疫球蛋白对比4%白蛋白治疗儿童中毒性休克综合征的随机对照可行性研究

High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study.
PubMed 文献 · Arch Dis Child · 2024-08-16

本研究为多中心、可行性、双盲随机对照试验,评估在休克发作12小时内使用大剂量静脉免疫球蛋白(IG)对比4%白蛋白(对照组)治疗儿童中毒性休克综合征(TSS)的可行性。共28例患者(IG组13例,对照组15例)接受分配治疗,纳入率超过50%,方案偏差低于30%,死亡和PELOD-2评分缺失数据低于10%。两组次要临床结局无差异,对照组不良事件报告更多。结论认为开展此类随机对照试验可行,但需在国际范围内进行,并选择临床相关终点和特定设计。

要点

  • 儿童TSS中开展大剂量静脉IG随机对照试验可行,纳入率>50%,方案偏差<30%。
  • 两组次要临床结局无差异,对照组不良事件报告更多。
  • 未来试验需国际化、选择临床相关终点和特定设计。

核心结论

  • 在儿童TSS中开展评估大剂量静脉IG疗效与安全性的随机对照试验是可行的。

研究设计与样本

  • 多中心、可行性、双盲随机对照试验,纳入年龄>1月且<18岁、疑似TSS和感染性休克的患者,在休克发作12小时内给予大剂量静脉IG或4%白蛋白(对照组)。
  • 共28例患者来自6个儿科重症监护病房,36个连续月内纳入并随访1年,IG组13例,对照组15例,中位年龄10.6岁,性别比1。

主要发现

  • 纳入率超过50%,方案偏差低于30%,死亡和PELOD-2评分缺失数据低于10%。
  • 两组次要临床结局无差异,对照组不良事件报告更多。

关键数值与推荐

  • 可行性指标:纳入率>50%,方案偏差<30%,死亡和PELOD-2评分缺失数据<10%。

临床怎么用

  • 结果表明可在儿童TSS中开展大剂量静脉IG的随机对照试验,但需国际协作、选择临床相关终点和特定设计以提高现实可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Toxic shock syndrome (TSS) is a rare disease responsible for significant morbidity and mortality. Intravenous immunoglobulin (IG) therapy in paediatric TSS could improve shock and organ failure, but more consistent efficacy and safety data are needed. Our objective was to determine whether a randomised clinical trial (RCT) assessing intravenous IG in TSS in children is feasible. METHODS: We performed a multicentre, feasibility, double-blind RCT assessing efficacy of high-dose intravenous IG versus albumin 4% (control group) within the first 12 hours of shock onset. Included patients were aged above 1 month and below 18 years with suspected TSS and septic shock. Feasibility was assessed by measuring inclusion rate, protocol compliance and missing data regarding death and the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) Score. Other secondary clinical outcomes were evaluated during hospital stay, at 60 day and 1 year. RESULTS: 28 patients, admitted in 6 paediatric intensive care units during 36 consecutive months and followed for 1 year, received the allocated treatment: 13 in intravenous IG group, 15 in control group. The median age was 10.6 years and the sex ratio was 1. Inclusion rate was above 50%, protocol deviations were below 30% and missing data regarding death and PELOD-2 Score below 10%. No difference concerning secondary clinical outcomes between groups was observed, and more adverse events were reported in the control group. CONCLUSION: It seems to be feasible to conduct an RCT assessing intravenous IG efficacy and safety in paediatric TSS but must be realised internationally, with choice of a clinically relevant endpoint and a specific design in order to be realistic. TRIAL REGISTRATION NUMBER: NCT02219165.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Portefaix A, Dhelens C, Recher M, et al. High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study. Arch Dis Child. 2024. PMID: 38360044. doi:10.1136/archdischild-2022-325274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。